Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Cellular & Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Drug Target. 2021 Aug;29(7):771-782. doi: 10.1080/1061186X.2021.1879087. Epub 2021 Jul 9.
PD-L1 overexpression on tumour cells forms a protective shield against cytotoxic T-cell killing, which consequently leads to immune evasion. Engagement of PD-1 in tumour infiltrating T cells with PD-L1 results in an exhausted T-cell phenotype, thus preventing an effective immune response against tumour cells. In the present study, we employed phage display combinatorial peptide library to discover anti-PD-L1 peptides. The peptides discovered here, could computationally exhibit specific interactions with PD-L1 at residues with which PD-1 also interacts. Binding affinity and specificity of the peptides were examined by flow cytometry. Anti- tumour activity of peptides was also investigated using several cell-based assays. Surprisingly, we demonstrated that Pep-39 can inhibit PDL-1, and reduce MDA-MB-231, CT-26, and DU-145 cells survival. In co-culture experiments, Pep-39 restored proliferation of Jurkat cells cultured in the presence of MDA-MB-231 cells. In addition, Jurkat cells apoptosis was impeded, indicating blocking potential of Pep-39 against PD-1/PD-L1 interaction.
肿瘤细胞上 PD-L1 的过度表达形成了一种对抗细胞毒性 T 细胞杀伤的保护屏障,从而导致免疫逃逸。PD-1 在肿瘤浸润 T 细胞与 PD-L1 的结合导致衰竭的 T 细胞表型,从而阻止了对肿瘤细胞的有效免疫反应。在本研究中,我们采用噬菌体展示组合肽文库来发现抗 PD-L1 肽。在这里发现的肽,可以通过计算与 PD-1 相互作用的残基与 PD-L1 表现出特异性相互作用。通过流式细胞术检查了肽的结合亲和力和特异性。还使用几种基于细胞的测定法研究了肽的抗肿瘤活性。令人惊讶的是,我们证明 Pep-39 可以抑制 PDL-1,并降低 MDA-MB-231、CT-26 和 DU-145 细胞的存活率。在共培养实验中,Pep-39 恢复了在 MDA-MB-231 细胞存在下培养的 Jurkat 细胞的增殖。此外,Jurkat 细胞的凋亡受到阻碍,表明 Pep-39 具有阻断 PD-1/PD-L1 相互作用的潜力。